Can We Use Antibodies to Chlamydia trachomatis as a Surveillance Tool for National Trachoma Control Programs? Results from a District Survey

• Sheila K. West ,

  * E-mail: shwest@jhmi.edu

  Affiliation Dana Center for Preventive Ophthalmology, Johns Hopkins University, Baltimore, Maryland, United States of America

  ⨯
• Beatriz Munoz,

  Affiliation Dana Center for Preventive Ophthalmology, Johns Hopkins University, Baltimore, Maryland, United States of America

  ⨯
• Jerusha Weaver,

  Affiliation Dana Center for Preventive Ophthalmology, Johns Hopkins University, Baltimore, Maryland, United States of America

  ⨯
• Zakayo Mrango,

  Affiliation National Institute for Medical Research, Kilosa, Tanzania

  ⨯
• Laura Dize,

  Affiliation Division of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland, United States of America

  ⨯
• Charlotte Gaydos,

  Affiliation Division of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland, United States of America

  ⨯
• Thomas C. Quinn,

  Affiliations Division of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland, United States of America, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, United States of America

  ⨯
• Diana L. Martin

  Affiliation Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

  ⨯